Abiopharma

AMPLIA THERAPEUTICS LTD. (INNMF)

Symbol	INNMF
Name	AMPLIA THERAPEUTICS LTD.
Sector	UNDEFINED
Region	Oceania
Industry	-
Address	3000 Australia VA Level 17, 350 Queen Street
Telephone	+61 3 9123 1140
Fax	—
Email	—
Website	https://www.ampliatx.com/site/content/
Incorporation	AU
Incorporated On	2016
Employees	—
Fiscal Year	3/31
Public Since	—
Exchanges	OTC
Auditor	Grant Thornton Australia;
Audit Status	AUDITED
Reporting Status	International Reporting: ASX - Australian Securities Exchange
CIK	—
Description	Amplia Therapeutics Limited, a pharmaceutical company, focuses on development of focal adhesion kinase (FAK) inhibitors for oncology and chronic fibrosis in Australia. The companys product pipeline includes AMP945, an inhibitor of FAK, for pancreatic cancer and idiopathic pulmonary fibrosis, as well as other cancers and fibrotic diseases indications, that has completed Phase I clinical trial; and AMP886 for cancer and fibrotic disease indication. It has a collaboration agreement with the Garvan Institute of Media Research in Sydney. Additional info from OTC: Amplia Therapeutics Limited, a pharmaceutical company, focuses on development of focal adhesion kinase (FAK) inhibitors for oncology and chronic fibrosis in Australia. The companys product pipeline includes AMP945, an inhibitor of FAK, for pancreatic cancer and idiopathic pulmonary fibrosis, as well as other cancers and fibrotic diseases indications, that has completed Phase I clinical trial; and AMP886 for cancer and fibrotic disease indication. It has a collaboration agreement with the Garvan Institute of Media Research in Sydney.

2026-08-04 12:45

Amplia Signs Collaboration Agreement With Lilly, Evaluating Narmafotinib Plus Lilly’s Kras G12C Inhibitor, Olomorasib, in Non-small Cell Lung Cancer

2026-07-31 12:45

Scientific Paper Detailing Preclinical Studies of Narmafotinib in Pancreatic Cancer Now Online

2026-07-07 12:45

Amplia Announces Appointment of Brett Carter to Board

2026-07-06 12:45

Amplia Announces Changes to Board’s Leadership Roles

2026-06-22 12:45

Following Significant Advances at ASCO, Amplia Therapeutics Provides Letter to Shareholders Highlighting the Potential Opportunities for Combination with KRAS Inhibition in Pancreatic Cancer

2026-05-19 12:45

Amplia Therapeutics Launches First Stage of Registration-Enabling Trial of Narmafotinib

2026-05-09 00:45

Amplia Therapeutics and Australia New Zealand Gynaecological Oncology Group (Anzgog) Announce Ovarian Cancer Study

2026-04-22 12:45

Accent Trial Mature Data Presented at International Conference

2026-03-23 12:45

Amplia Therapeutics Reports Four Additional Complete Responses and Improved Overall Survival Data in Accent Pancreatic Cancer Trial

2026-03-09 12:45

Poster Presentation Demonstrating Combination Benefit of Narmafotinib in Preclinical Kras-Mutated Cancer Models